RHYTHM PHARMACEUTICALS, INC.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	September 30,2026	December 31,2025
Assets
Current assets:
Cash and cash equivalents	$39,981	$54,301
Short-term investments	280,963	334,648
Accounts receivable, net	39,120	26,081
Inventory	31,187	25,753
Prepaid expenses and other current assets	28,111	26,133
Total current assets	419,362	466,916
Property and equipment, net	569	1,104
Right-of-use asset	2,694	3,049
Intangible assets, net	16,678	5,319
Restricted cash	1,281	522
Other long-term assets	2,548	3,286
Total assets	$443,132	$480,196
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable	$10,687	$13,947
Accrued expenses and other current liabilities	124,721	83,855
Lease liability	731	650
Deferred revenue	—	194
Deferred royalty obligation, current	14,751	7,296
Total current liabilities	150,890	105,942
Long-term liabilities:
Deferred royalty obligation	87,915	100,886
Lease liability, non-current	2,784	3,342
Total liabilities	241,589	210,170
Commitments and contingencies (Note 14)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively. Liquidation preference of $116,725 and $132,500 as of September 30, 2026, and December 31, 2025, respectively.	113,577	130,957
Stockholders’ equity:
Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares issued and outstanding at September 30, 2026 and December 31, 2025	—	—
Common stock, $0.001 par value: 120,000,000 shares authorized; 69,314,825 and 67,205,321 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	70	67
Additional paid-in capital	1,587,823	1,491,675
Accumulated other comprehensive loss	(1,744)	(796)
Accumulated deficit	(1,498,183)	(1,351,877)
Total stockholders’ equity	87,966	139,069
Total liabilities, convertible preferred stock and stockholders’ equity	$443,132	$480,196

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.